amediplase

a recombinant chimeric plasminogen activator, consisting of the kringle 2 domain from the A-chain of tissue plasminogen activator (t-PA) and the carboxy terminal region of pro-urokinase

Also Known As:

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Doggrell, Sheila A: 1 article (03/2004)

Related Diseases

1.	Thrombosis (Thrombus) 05/03/1993 - "The concentration producing 50% lysis of blood clots in 3 h was 0.5 microgram/ml for K2tu-PA and 1 microgram/ml for FK2tu-PA, as compared to 0.5 microgram/ml and > 2 micrograms/ml for t-PA and scu-PA, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)" 08/02/1993 - "The aim of this study was to compare the effects of bolus doses of recombinant t-PA (rt-PA) and K2tu-PA, on: 1) lysis of performed thrombi (fibrinolysis), 2) accretion of new fibrin on pre-existing thrombi during fibrinolysis (thrombus growth), 3) thrombolysis as assessed by reduction of thrombus weight and 4) systemic plasma proteolysis and blood loss from a standard wound. " 03/01/2004 - "Amediplase, a chimeric protein containing functional domains of both tissue plasminogen activator and pro-urokinase plasminogen activator, is under development by Menarini for the potential treatment of thrombosis. "
2.	Wounds and Injuries (Trauma) 08/02/1993 - "The aim of this study was to compare the effects of bolus doses of recombinant t-PA (rt-PA) and K2tu-PA, on: 1) lysis of performed thrombi (fibrinolysis), 2) accretion of new fibrin on pre-existing thrombi during fibrinolysis (thrombus growth), 3) thrombolysis as assessed by reduction of thrombus weight and 4) systemic plasma proteolysis and blood loss from a standard wound. "
3.	Myocardial Infarction 01/01/2002 - "Menarini is currently investigating amediplase in phase III clinical trials in Europe as a thrombolytic given as a single bolus to patients with myocardial infarction. "

Related Drugs and Biologics

1.	Fibrin
2.	Proteins (Proteins, Gene)
3.	Plasminogen Activators (Plasminogen Activator)
4.	Tissue Plasminogen Activator (Alteplase)
5.	saruplase